Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-31
2007-07-31
Aulakh, Charanjit S. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S291000, C546S290000, C546S269100, C546S268400
Reexamination Certificate
active
10781062
ABSTRACT:
Compounds of the formula:useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils.
REFERENCES:
patent: 4157395 (1979-06-01), Hitzel et al.
patent: 4181658 (1980-01-01), Hitzel et al.
patent: 4692185 (1987-09-01), Michaely
patent: 4861891 (1989-08-01), Saccomano et al.
patent: 5552438 (1996-09-01), Christensen, IV
patent: 5602157 (1997-02-01), Christensen, IV
patent: 5614540 (1997-03-01), Christensen, IV
patent: 5863926 (1999-01-01), Christensen, IV et al.
patent: 5922557 (1999-07-01), Pon
patent: 6380218 (2002-04-01), Marfat et al.
patent: 0023569 (1983-06-01), None
patent: 0550900 (1992-12-01), None
patent: 0661274 (1995-07-01), None
patent: 0500989 (1998-12-01), None
patent: 2140772 (1973-01-01), None
patent: 2327675 (1999-02-01), None
patent: 7304775 (1995-11-01), None
patent: WO 9500139 (1995-01-01), None
patent: WO 9818796 (1998-05-01), None
patent: WO 9845268 (1998-10-01), None
patent: WO 9918793 (1999-04-01), None
patent: WO 9920280 (1999-04-01), None
patent: WO 9920625 (1999-04-01), None
patent: WO 0157025 (2001-08-01), None
patent: WO 0157036 (2001-08-01), None
Trophy, Theodore J. et al., “Phosphodiesterase IV Inhibitors as Therapy for Eosinophil-induced Lung Injury in Asthma,” Environmental Health Perspectives, vol. 102 Suppl. 10, Dec. 1994, pp. 79-84.
Duplantier, Allen J., et al., “Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [3H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret, Journal of Medicinal Chemistry,” 1996, vol. 39, No. 1, pp. 120-125.
Schneider, Herbert H, et al, “Dicriminative Stimulus Properties of the Stereoisomers of the Phosphodiesterase Inhibitor Rolipram,” Pharmacology Biochemistry and Behavior, vol. 50, No. 2, 1995, pp. 211-217.
Banner, Katherine H., et. al., “Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs,” British Journal of Pharmacology, 114, 1995, pp. 93-98.
Barnette, Mary S., et. al., “The Ability of Phosphodiesterase IV Inhibitors to Suppress Superoxide Production in Guinea Pig Eosinophils Is Correlated with Inhibition of Phosphodiesterase IV Catalytic Activity,” The Journal of Pharmacology and Experimental Therapeutics, 273, 1995 pp. 674-679.
Wright, Kathryn, F., et al., “Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor, ”Can. J. Physiol. Pharmacol. 75, 1997, pp. 1001-1008.
Manabe, Haruhiko, “Anti-inflammatory and Bronchodilator Properties of KF19514, a Phosphodiesterase 4 and 1 Inhibitor,” European Journal of Pharmacology, 332, 1997, pp. 97-107.
Ukita, Tatsuzo, et. al., Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridylnaphthalene Derivatives, J. Med. Chem, 48, 1999, pp. 1088-1099.
Compton, CH, et. al., The Efficacy of Ariflo™ (SB 207499, A Second Generation, Oral PDE4 Inhibitor, In Patients with COPD, Am. J. Respir. Crit. Care Med., 159, 1999.
Leeman, Marc M.D., et al., “Reduction in Pulmonary Hypertension and in Airway Resistances by Enoximone (MDL 17,043) in Decompensated COPD*,” Chest, 91, 1987, pp. 662-666.
Rabe, K.F., et al., “Identification of PDE Isozymes in Human Pulmonary Artery and Effect of Selective PDE Inhibitors,” Am. J. Physiol, 266 (LCMP 10), 1994, pp. L536-L543.
Hughes, Bernadette, et. al., PDE 4 Inhibitors: the use of molecular cloning in the design and development of novel drugs, Drug Discovery Today, Science Direct, 2(3), 1997 pp. 89-101.
Banner, K.H., et al., “The Effect of Selective Phosphodiesterase Inhibitors in Comparison with other Anti-asthma Drugs on Allergen-inducedEosinophiliain Guinea-pig Airways,” Pulmonary Pharmacology, 8, 1995, pp. 37-42.
Raebum, David, et.al., “Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase typed IV inhibitor,” Br, J. Pharmacol., 113, 1994, pp. 1423-1431.
Karlsson, J.A., et. al., “Anti-Inflammatory Effects of the Novel Phosphodiesterase IV Inhibitor RP 73401,” Int. Arch Allergy Immunol, 107, 1995, pp. 425-426.
Escott, K.J., et. al., Pharmacological Profiling of Phosphodiesterase, 4 (PDE4) Inhibitors and Analysis of the Therapeutic Ratio in Rats and Dogs, Br. J. Pharmacol, 123 (Proc suppl.) 1998 40P.
Landells, L.J., et. al., “Oral Administration of the Phosphodiesterase (PDE) 4 Inhibitor, V11294A Inhibits Ex-Vivo Agonist-induced Cell Activation,” Eur. Resp. J., 12 (Suppl. 28), 362s, 1998, P2393.
Gale, D.D., et. al., “Pharmacodynamic-Pharmacokinetic (PD/PK) Profile of the Phosphodiesterase (PDE)4 Inhibitor, V11294A, in Human Volunteers,” Am. J. Respir. Crit Care Med., 159, A611, 1999, pp. A108.
Montana, J., et. al., “Activity of D4418, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, Effects in Cellular and Animal Models of Asthma and Early Clinical Studies,” Am. J. Respir. Crit., Care Med., 159, A108, 1999, pp. A624.
Cavalla, D., et al., “Activity of V11294A, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, In Cellular and Animal Models of Asthma,” Am. J. Respir. Crit. Care Med. 155, 1997, pp. A660.
Pascal, Y., et. al., “Synthesis and Structure,-activity Relationships of 4-oxo-1 pheyl-3,4,5,7-Tetrahydro-[1,4]Diazepino[6,7,1-HI]Indolines: Novel PDE4 Inhibitors,” 215thACS, MEDI, 50, 1998.
Bumouf, C., et. al., “Pharmacology of the Novel Phosphodiesterase Type 4 Inhibitor, CI-1018,” 215thACS, MEDL 008, 1998.
Mueller, George W., et. al., N-Phthaloyl-β- Aryl- β- Amino Derivatives Potent TNF-α And PDE4 Inhibitors, MEDI, 299, 1999.
Mueller, George W., et. al., “Thalidomide Analogs and PDE4 Inhibition,” Bioorganic & Medicinal Chemistry Letters, 8, 1998 pp. 2669-2674.
Takayama, K., “Synthetic Studies on Selective Type IV Phosphodiesterase (PDE IV) Inhibitors,” MEDI 245, 1997.
Gordon, T., et. al., “Anti-Inflammatory Effects of a PDE4 Inhibitor in a Rat Model of Chronic Bronchitis,” Am. J. Respir. Crit. Care Med., 159, A33, 1999.
Perrier, Helene, et. al., “Substituted Furans as Inhibitors of the PDE4 Enzyme,” Bioorganic & Medicinal Chemistry Letters 9, 1999, pp. 323-326.
Groneberg, Robert D., et. al., “Dual Inhibition of Phosphodiesterase 4 and Matrix Metalloproteinases by an (Arylsulfonyl)hydroxamic Acid Template,” Journal of Medicinal Chemistry, 1999, vol. 42, No. 4, 541-544.
Fujimura, Masaki, et. al., Bronchoprotective Effects of KF-19514 and Cliostazol in Guinea Pigs In Vivo, European Journal of Pharmacology, 327, 1997, pp. 57-63.
Manabe, Haruhiko, et. al., “KF19514, a Phosphodiesterase 4 and 1 Inhibitor, Inhibits PAF-Induced Lung Inflammatory Responses by Inhaled Administration in Guinea Pigs,” International Archives of Allergy-Immunology, 1997, 114, pp. 389-399.
Suzuki, Fumio, et. al., “New Bronchodilators, 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones,” Journal of Medicinal Chemistry, 1992, vol. 35, No. 26, pp. 4866-4874.
Matsuura, Akihiro, et. al., “Substituted 1,8-Naphthyridin-2(1H)-ones as Selective Phosphodiesterase IV Inhibitors,” Biol. Pharm. Bull. vol. 17(4), 1994, pp. 498-503.
Manabe, Haruhiko, et. al., “Pharmacological properties of a New Bronchodilator, KF17625,” Jpn. J. Pharmacol., 58 (Suppl 1)., 1992 pp. 238.
Montana, John G., et. al., “PDE4 Inhibitors: New Xanthine Analogues,” Bioorganic & Medicinal Chemistry Letters 8, 1998, pp. 2925-2930.
Merz, Karl-Heinz, et. al., “Synthesis of 7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and Novel Derivatives Free of Positional Isomers. Potent Inhibitors of cAMP-Specific Phosphodiesterase and of Malignant Tumor Cell Growth,” Journal of Medicinal Chemistry, vol. 41, N
Chambers Robert J.
Magee Thomas V.
Marfat Anthony
Ashbrook Charles W.
Aulakh Charanjit S.
Goodman Rosanne
Misiak Paul M.
Pfizer Inc.
LandOfFree
Nicotinamide acids, amides, and their mimetics active as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotinamide acids, amides, and their mimetics active as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotinamide acids, amides, and their mimetics active as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3751132